全文获取类型
收费全文 | 216272篇 |
免费 | 4337篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 1445篇 |
儿科学 | 8178篇 |
妇产科学 | 4218篇 |
基础医学 | 21361篇 |
口腔科学 | 2205篇 |
临床医学 | 19627篇 |
内科学 | 37836篇 |
皮肤病学 | 1249篇 |
神经病学 | 20206篇 |
特种医学 | 9769篇 |
外科学 | 32407篇 |
综合类 | 2868篇 |
一般理论 | 88篇 |
预防医学 | 23875篇 |
眼科学 | 3177篇 |
药学 | 11808篇 |
中国医学 | 653篇 |
肿瘤学 | 19720篇 |
出版年
2023年 | 269篇 |
2022年 | 349篇 |
2021年 | 772篇 |
2020年 | 606篇 |
2019年 | 1064篇 |
2018年 | 22829篇 |
2017年 | 18037篇 |
2016年 | 20299篇 |
2015年 | 1891篇 |
2014年 | 2120篇 |
2013年 | 2819篇 |
2012年 | 9730篇 |
2011年 | 23842篇 |
2010年 | 20286篇 |
2009年 | 12887篇 |
2008年 | 22071篇 |
2007年 | 24428篇 |
2006年 | 3260篇 |
2005年 | 4832篇 |
2004年 | 5889篇 |
2003年 | 6704篇 |
2002年 | 4734篇 |
2001年 | 779篇 |
2000年 | 860篇 |
1999年 | 635篇 |
1998年 | 766篇 |
1997年 | 618篇 |
1996年 | 489篇 |
1995年 | 483篇 |
1994年 | 418篇 |
1993年 | 368篇 |
1992年 | 384篇 |
1991年 | 406篇 |
1990年 | 425篇 |
1989年 | 369篇 |
1988年 | 320篇 |
1987年 | 281篇 |
1986年 | 262篇 |
1985年 | 290篇 |
1984年 | 228篇 |
1983年 | 230篇 |
1982年 | 235篇 |
1981年 | 210篇 |
1980年 | 243篇 |
1979年 | 127篇 |
1978年 | 140篇 |
1977年 | 107篇 |
1976年 | 90篇 |
1975年 | 78篇 |
1974年 | 95篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
42.
Kalaichelvi Ganesalingam Ann Sanson Vicki Anderson Keith Owen Yeates 《Journal of the International Neuropsychological Society》2006,12(5):609-621
This study examined the impact of childhood traumatic brain injury (TBI) on self-regulation and social and behavioral functioning, and the role of self-regulation as a predictor of children's social and behavioral functioning. Participants included 65 children with moderate to severe TBI and 65 children without TBI, all between 6 and 11 years of age. Self-regulation and social and behavioral functioning were assessed 2 to 5 years following injury. Children with TBI displayed deficits in self-regulation and social and behavioral functioning, after controlling for socioeconomic status (SES), although the magnitude of the deficits was not related to injury severity. Self-regulation accounted for significant variance in children's social and behavioral functioning, after controlling for SES and group membership. Self-regulation may be an important determinant of children's social and behavioral functioning following TBI. 相似文献
43.
44.
45.
46.
47.
48.
We have previously reported the time trends, design and interventions in randomised controlled trials (RCTs) in cystic fibrosis (CF) from 1961 through 1997 [Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D, Randomised controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol 2000, 29:1-7.]. We maintain an ongoing register of all RCTs and controlled clinical trials (CCTs) in CF and have noted that in the five years since 1997 there has been a 48% increase in published trials. We aimed to assess whether this increase has been associated with an improvement in design quality. All RCTs and CCTs from 1961-2002 were assessed. Two epochs were then compared, 1961-1997 and 1998-2002. For each trial we recorded the design, participant numbers and the intervention studied. 261 trials in 1998-2002 were compared with 544 trials in 1961-1997. Comparing the two epochs a similar proportion of trials were parallel, double-blind and placebo controlled; also the median number of participants was similar. In the later epoch 25% of trials were multicentre, compared with 11% previously. Whilst this recent increase in clinical trials in CF is welcome, this has not been associated with improvements in quality. The trend for an increasing proportion of trials to be multicentre is encouraging. There are however, still deficiencies in the design of clinical trials in CF. 相似文献
49.
50.